Identification | Back Directory | [Name]
N-(2-Bromophenyl)-N'-[2-[ethyl(3-methylphenyl)amino]ethyl]-urea | [CAS]
459429-39-1 | [Synonyms]
SB 452533 SB 452533 >=98% (HPLC) SB 452533, 10 mM in DMSO 1-(2-broMophenyl)-3-(2-(ethyl(M-tolyl)aMino)ethyl)urea N-(2-Bromophenyl)-N'-[2-[ethyl(3-methylphenyl)amino]ethyl]-urea Urea, N-(2-bromophenyl)-N'-[2-[ethyl(3-methylphenyl)amino]ethyl]- ATP,glucose oxidation,inhibit,ERK1/2,TRPV1,SB 452533,pulmonary,TRP Channel,fibrosis,SB452533,CAMKK2,skeletal muscle,SB-452533,capsaicin,Inhibitor,Transient receptor potential channels | [Molecular Formula]
C18H22BrN3O | [MDL Number]
MFCD19690909 | [MOL File]
459429-39-1.mol | [Molecular Weight]
376.29 |
Chemical Properties | Back Directory | [Boiling point ]
481.7±45.0 °C(Predicted) | [density ]
1.347±0.06 g/cm3(Predicted) | [storage temp. ]
Store at RT | [solubility ]
DMSO: soluble20mg/mL, clear | [form ]
powder | [pka]
13.43±0.46(Predicted) | [color ]
yellow to orange |
Hazard Information | Back Directory | [Uses]
SB 452533 is a potent, selective and orally bioavailable TRPV1 antagonist. | [in vivo]
Capsaicin (Cap; small dose 2 mg/kg) significantly reduces Bleomycin-induced pulmonary fibrosis in mice. SB-452533 abolishes the effects of small dose Cap[3]. Animal Model: | BALB/c mice bearing pulmonary fibrosis model[3] | Dosage: | 2.5 mg/kg | Administration: | Treatment received daily drug via subcutaneous injection for 21 days | Result: | The effect (reduced Bleomycin-induced pulmonary fibrosis) of Cap were abolished in the presence of SB-452533.
|
|
|
Company Name: |
BOC Sciences
|
Tel: |
|
Website: |
https://www.bocsci.com |
Company Name: |
Energy Chemical
|
Tel: |
021-58432009 400-005-6266 |
Website: |
http://www.energy-chemical.com |
|